Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

• Autores principales: Mariana Vieira Morau (Autor), Cecilia Souto Seguin (Autor), Mauricio Wesley Perroud Junior (Autor), Carolina Dagli-Hernandez (Autor), Eder de Carvalho Pincinato (Autor), Patricia Moriel (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2024-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Gefitinib is a selective inhibitor of the epidermal growth factor receptor that is used to treat advanced and metastatic non-small cell lung cancer (NSCLC). Dermatological adverse reactions are most commonly associated with gefitinib treatment. The cause of adverse reactions in individuals is multif...